Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with ...

Elanco Animal Health Incorporated announced today that its Canine Parvovirus Monoclonal Antibody (CPMA) has become the first US Department of Agriculture conditionally approved treatment that targets ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Patients with bronchiectasis and a Pseudomonas aeruginosa infection receiving gremubamab, a bispecific monoclonal antibody, ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne ...

Use of an investigational monoclonal antibody called bimagrumab added to semaglutide produced weight loss while preserving ...

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...